VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
VRDN
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
HomeStocksVRDNInstitutional Holders

VRDN logoViridian Therapeutics, Inc. (VRDN) Institutional Ownership

Q2 2026 13F Data|Updated 2026-11-18

✨

Institutional ownership increased this quarter (+12.81 pp), though top 10 holders maintain a highly concentrated 51.9% of institutional value.

Institutional Ownership
Can exceed 100% due to securities lending, short interest, and reporting timing differences.
151.5%$2.4B total value · ▲ +12.81 pp vs prior quarter
Smart Money Score
Based on ownership concentration, fund quality, buying/selling activity, ownership indicators, and institutional trend.
60 / 100Bullish
Institutions & Flow218 holders-8 net flow (+44 / -52)

AI Insights & Key Takeaways

  • Negative Institutional Flow (-8)
  • Point72 Asset Management, L.p. and Fisher Asset Management, Llc maintain significant positions
  • Top 10 holders control 51.9% of institutional value
  • No Insider Signal

Top Institutional Holders of VRDN

Ranked by reported Q2 2026 13F market value

Top 10 Holders
51.9%
Top 25 Holders
76.2%

Share of total reported institutional value in VRDN held by the largest 10 / 25 filers.

#InstitutionShares HeldMarket ValueQoQ ChangeOwnership %% of Fund
1FMR LLC16.6M$305.0M+8.0%18.450%0.01%
2BlackRock, Inc.8.6M$157.1M+9.2%9.502%0.00%
3Bellevue Group AG6.7M$123.7M+0.1%7.480%2.60%
4

Quarterly Institutional Activity

Filings activity in VRDN during Q2 2026, grouped by how each filer changed its position.

OverviewNew Buyers44Added To90Trimmed79Exited52
  • FMR LLC$305.0M
  • BlackRock, Inc.$157.1M
  • Paradigm Biocapital Advisors LP

VRDN Institutional Ownership by Quarter

8 quarters of 13F filings · Δ columns show change vs prior quarter

QuarterInst. HoldersΔ HoldersOwnership %Δ OwnershipTotal 13F ValueΔ Value
Q2 20262183.5%151.51%+12.81 pp$2.40B+11%
Q1 20262260.4%138.70%+5.62 pp$2.16B33%
Q4 2025227+37%133.08%9.49 pp$3.23B+65%
Q3 20251663.5%142.57%3.30 pp$1.96B+53%
Q2 20251721.7%145.87%+4.82 pp$1.28B+7.5%
Q1 2025175

How VRDN Compares to Peers

Institutional ownership and quarterly buying activity across the largest Immunology Biotech peers.

TickerCompanyMarket CapInst. OwnershipHoldersNet Buyers − Sellers
LKFTLakefront Biotherapeutics N.V.$2.19B49.6%79-12
YARWYarrow Bioscience Inc$145M1.2%47+2
RKTORocket One Inc.$9M7.9%22+3

VRDN — Frequently Asked Questions

Quick answers to the most common questions about buying VRDN stock.

What percentage of VRDN is owned by institutions?

Based on Q2 2026 13F filings, institutional ownership of Viridian Therapeutics, Inc. stands at 151.5%, held across 218 reporting institutions.

Who is the largest institutional holder of VRDN?

FMR LLC is the largest reported institutional holder of VRDN, with approximately 16,604,740 shares worth $0.31B as of Q2 2026.

Is VRDN a hedge fund favorite?

Yes — 2 widely-followed marquee investors appear among the top 25 institutional holders of VRDN, including Point72 Asset Management, L.P., Fisher Asset Management, LLC.

What is VRDN's Smart Money Score?

Our composite Smart Money Score for VRDN is 60 out of 100 (Bullish). It combines net institutional buying activity, ownership shift, marquee investor presence, and holder-count growth.

How many institutions bought VRDN this quarter?
Paradigm Biocapital Advisors LP
6.7M
$123.5M
+113.5%
7.471%
2.31%
5Kynam Capital Management, LP6.5M$118.6M+175.6%7.171%6.55%
6STATE STREET CORP6.1M$112.5M+31.1%6.806%0.00%
7Fairmount Funds Management LLC5.1M$93.5M+30.0%5.657%6.18%
8VANGUARD CAPITAL MANAGEMENT LLC4.6M$84.1M+9.8%5.085%0.00%
9Deep Track Capital, LP3.6M$66.0M+157.7%3.992%0.96%
10Venrock Adviser, LLC3.3M$59.8M-16.1%3.620%1.81%
11WELLINGTON MANAGEMENT GROUP LLP3.1M$57.5M+1.6%3.476%0.01%
12VANGUARD PORTFOLIO MANAGEMENT LLC2.8M$50.6M+67.7%3.059%0.00%
13GEODE CAPITAL MANAGEMENT, LLC2.5M$46.0M+7.2%2.780%0.00%
14Avoro Capital Advisors LLC2.5M$45.9M+66.7%2.778%0.41%
15BAKER BROS. ADVISORS LP2.4M$43.8M+20.9%2.648%0.22%
16Point72 Asset Management, L.P.2.4M$43.3M+629.9%2.618%0.05%
17Caligan Partners LP2.2M$40.3M—2.438%1.90%
18Novo Holdings A/S2.1M$39.2M+6.8%2.372%2.28%
19TANG CAPITAL MANAGEMENT LLC1.8M$32.9M0.0%1.992%1.50%
20Fisher Asset Management, LLC1.8M$32.2M-1.0%1.945%0.01%
21Candriam S.C.A.1.7M$31.3M+139.9%1.897%0.14%
22GOLDMAN SACHS GROUP INC1.7M$31.1M+6.2%1.879%0.00%
23First Turn Management, LLC1.7M$30.7M+83.3%1.856%3.28%
24DIMENSIONAL FUND ADVISORS LP1.6M$29.6M+204.2%1.791%0.01%
25ALLIANCEBERNSTEIN L.P.1.4M$27.2M-0.0%1.546%0.01%

denotes a marquee investor (Buffett, Burry, ARK, Tiger Global, Pershing Square, Baupost and other widely-followed managers). “% of Fund” shows how much of that investor’s total 13F portfolio is invested in VRDN — a direct measure of their conviction.

$123.5M
  • Kynam Capital Management, LP$118.6M
  • STATE STREET CORP$112.5M
  • Fairmount Funds Management LLC$93.5M
  • VANGUARD CAPITAL MANAGEMENT LLC$84.1M
  • Deep Track Capital, LP$66.0M
  • VANGUARD PORTFOLIO MANAGEMENT LLC$50.6M
  • GEODE CAPITAL MANAGEMENT, LLC$46.0M
  • Avoro Capital Advisors LLC$45.9M
  • BAKER BROS. ADVISORS LP$43.8M
  • +0.0%
    141.05%
    +1.75 pp
    $1.19B
    28%
    Q4 2024175+8.0%139.30%+2.53 pp$1.65B15%
    Q3 2024162—136.77%—$1.94B—

    Source: SEC 13F institutional filings. Ownership % requires market cap data and will show once linked. Δ columns compare to the immediately prior filed quarter.

    44 institutions opened new positions in VRDN during Q2 2026, while 52 fully exited. 90 added to existing positions and 79 trimmed.

    How is institutional ownership of VRDN changing?

    VRDN institutional ownership rose by 12.81 percentage points quarter-over-quarter, with a net change of -8 holders.

    How concentrated is VRDN ownership among the top holders?

    The top 10 institutions account for 51.9% of all reported 13F value in VRDN, and the top 25 account for 76.2%.

    How does VRDN compare to Immunology Biotech on institutional ownership?

    Across the largest Immunology Biotech peers, institutional ownership levels are: LKFT (49.6%), YARW (1.2%), RKTO (7.9%). See the peer comparison table on this page for net buyer activity by company.

    Where does this VRDN institutional ownership data come from?

    All data is sourced from SEC Form 13F filings, which institutional investment managers with at least $100M in assets are required to file each quarter. We process every 13F filing from EDGAR and recompute the aggregates after each cycle. Insider transactions are sourced from Form 4 filings.

    VRDNViridian Therapeutics, Inc.
    $30.12$2.7B
    Overview & Tools
    OverviewChart Terminal ↗Visualize
    Valuation & Forecasts
    Valuation ModelsEstimatesDCF Model
    Price & Analyst Data
    Analyst TargetsPrice History
    Financial Statements
    Income StatementBalance SheetCash FlowRatios & Margins
    Performance
    P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
    Discovery & Screens
    Live BreakoutsStock ScreenerOwnership